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Abstract
Background: The present study measured the performance of the Papanicolaou (Pap) test and detection of cervical
carcinoma in situ (CIS) and cancer in participants of organized cervical cancer screening in South Korea, and examined
differences in the proportion of CIS according to socio-demographic factors.
Methods: Data were obtained from the National Cancer Screening Program and National Health Insurance Cancer
Screening Program databases. We analyzed data from 4,072,997 screenings of women aged 30 years or older who
underwent cervical cancer screening by Pap test between January 1, 2005 and December 31, 2006. We calculated the
performances of the Pap test and compared that according to socio-demographic factors.
Results: The positivity rate for all screenings was 6.6%. The cancer detection rate (CDR) and interval cancer rate (ICR) were
0.32 per 1,000 screenings, and 0.13 per 1,000 negative screenings, respectively. About 63.4% of screen-detected CIS+ cases
(CIS or invasive cervical cancer) were CIS. The CDR and ICR, and percentage of CIS among all CIS+ were significantly different
by age group and health insurance status. The odds ratios of CDR and ICR were higher for Medical Aid Program (MAP)
recipients compared with National Health Insurance (NHI) beneficiaries. The likelihood of a detected CIS+ case to be CIS was
significantly lower among MAP recipients than among NHI beneficiaries.
Conclusions: The difference in performance of cervical cancer screening among different socio-demographic groups may
indicate an important influence of socio-demographic factors on preventive behavior. The findings of the study support the
critical need for increasing efforts to raise awareness and provide more screening in at-risk populations, specifically low-
income groups.
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Introduction
Despite decreasing cervical cancer incidence and mortality rates
in developed countries, cervical cancer remains the third most
commonly diagnosed cancer and the third most common cause of
cancer mortality among women worldwide [1]. In South Korea,
the age-standardized incidence rate of cervical cancer in 2007 was
10.7 per 100,000 women, and cervical cancer was the seventh
most common cancer among women. However, the average
annual percentage change for 1999–2007 was 24.8%, which
shows that cervical cancer is continuously decreasing in Korea [2].
Despite decreasing cervical cancer incidence, the incidence of
cervical carcinoma in situ (CIS), a precursor of cervical cancer, is
continuously increasing. The age-standardized incidence rate of
CIS was 8.6 per 100,000 in 1993 and 12.4 per 100,000 in 2002
[3]. Furthermore, the percentage of CIS among all cervical
malignancy has increased from 28.5% in 1993 to 40.8% in 2002
[4]. The decreasing trend in cervical cancer incidence and the
increasing trend in CIS incidence could largely be due to the
introduction of cervical cancer screening in South Korea in the
late 1980s. Indeed, the increase in CIS incidence parallels an
increase in the use of the Papanicolaou (Pap) test for cervical
cancer screening, which has made the detection of CIS much
more likely than in the past.
Although cervical cancer incidence and mortality rates are
decreasing, the worldwide issue of unequal incidence and
mortality by socioeconomic status remains. In many countries, it
has been reported that lower income groups have higher cervical
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[5,6,7,8]. In Korea, Kim et al. [9] showed that cervical cancer
incidence and mortality are unfavorably unequal in lower income
groups. Indeed, the benefits of cervical cancer screening and
resulting early detection are not shared by all segments of the
population. It has been reported that high poverty levels are
related to low screening rates [10,11], and low-income and
minority women tend to be diagnosed at later stages and have
higher mortality rates [12,13,14,15,16,17,18,19]. Also, the well-
known risk factors of cervical cancer such as smoking and HPV
infection were more common in subjects with lower socioeco-
nomic status than higher one [20,21].
The effectiveness of cervical cancer screening has been assessed
over the past 30 years [22,23,24,25]. In Korea, organized cervical
cancer screening programs were introduced in 1988. Jun et al.
[26] evaluated the effectiveness of the organized cervical cancer
screening program in Korea and showed that regular cervical
cancer screening reduced the risk of invasive cervical cancer (ICC)
and CIS by 71% and 66%, respectively, in Korean women.
However, only limited information is currently available on the
performance of cervical cancer screening. As evaluation of
performance indicators are the basis for the establishment of
quality Korean cervical cancer screening program. This study
provides detailed estimates of key outcome measures, including
positivity rate, cancer detection rate and interval cancer rate
(ICR). In addition, we determined the percentage of CIS among
screen detected CIS+ (CIS or invasive cervical cancer) according
to the socio-demographic factors.
Methods
Korean organized cervical cancer screening program
In 1988, the National Health Insurance Screening Program
(NHISP) introduced an organized cervical cancer screening
program, which provides free biennial Pap tests to National
Health Insurance (NHI) beneficiaries aged 30 years or over. In
1999 the National Cancer Screening Program (NCSP) began
offering the same screening opportunities to Medical Aid Program
(MAP) recipients. Women in the target population receive an
invitation letter from the NHI Corporation at the beginning of
every other year.
Women invited voluntarily decide whether to make a screening
appointment. They can do so at any clinic or hospital that is
certified as a screening unit. During the screening visit they are
asked to complete a cancer screening information sheet, and are
subsequently screened. Results are usually sent to participants
within 15 days. In individuals with a positive Pap test at screening,
the organized cervical cancer screening guidelines recommend
follow-up by either colposcopy or repeat Pap test. However, this
follow-up test is not covered by the organized screening program,
but by the NHI [27,28].
Study population
The present study was restricted to women aged 30 years or
over who had undergone cervical cancer screening by Pap test
through the NSCP or NHISP between January 1, 2005 and
December 31, 2006. In total, 4,090,143 Pap test results were
eligible for inclusion during this period. We then proceeded to
exclude 607 (0.01%) missing screening results, 7,723 (0.19%)
previous ICC diagnoses, and 8,816 (0.21%) previous CIS
diagnoses, according to the Korean Central Cancer Registry
(KCCR). Therefore the current analysis was based on 4,072,997
screenings.
The NCSP and NHISP databases included participants’
demographic characteristics and screening results with written
informed consents. We collected these data regularly from the
NHI Corporation. As the NCSP and NHISP collect routine
medical and health data, obtaining informed consent for this
specific study was not necessary; this study was approved by the
institutional review board of the National Cancer Center, Korea.
Participant characteristics, Pap test assessment, and
cancer diagnoses
Women provided information on socio-demographic charac-
teristics, including age, health insurance status, health insurance
premium per month and Residence Registration Number (RRN; a
unique 13-digit number assigned to all Koreans). We used health
insurance status (MAP vs. NHI) and NHI premium level as a
proxy for socioeconomic status. These indicators have been
regarded as a highly reliable proxy for real income [29]. Hence
individuals were classified into three groups: MAP recipients
(extremely poor people who received livelihood assistance and
were unable to pay for health care or insurance); NHI beneficiaries
with a premium under 50%; and NHI beneficiaries with a
premium at 50% or above.
Pap tests (conventional cytology) were conducted by medical
staff at local hospitals following a standardized procedure. Pap test
results were reported using the Bethesda System, i.e., normal,
infection/inflammation/reactive change, atypical squamous cells
of undetermined significance, low-grade squamous intraepithelial
lesion, high-grade squamous intraepithelial lesion, suggestive of
squamous cell carcinoma, and other. Most Pap test results in the
other category were glandular abnormalities (e.g., glandular
atypia, atypical endocervical glands). A letter was sent to all
participants with the overall test result, reported according to four
categories: I, negative; II, benign; III, suspicious; IV, highly
suggestive of malignancy. Results were defined as abnormal if an
epithelial cell abnormality was reported and was coded as
‘‘suspicious’’ or ‘‘highly suggestive of malignancy’’ in the overall
test results.
The final diagnosis was ascertained through linkage with the
KCCR using the RRN, a nationwide hospital-based system that
contains 95% of newly diagnosed malignancies in Korea [30]. In
the KCCR, all malignant neoplasms and in situ cases are classified
according to the International Classification of Diseases for
Oncology, 3rd edition [31] and converted according to the
International Classification of Diseases, 10th edition (ICD-10)
[32]. We used the data on cancer diagnoses reported to the
KCCR up to December 2007 to account for a 12-month period
after screening, so that any follow-up or diagnostic work-up could
be completed and the results fully reported. In the KCCR, cervical
intraepithelial neoplasia is not registered; therefore, only cases of
ICC (ICD-10: C53) and CIS (ICD-10: D06) were included in this
study.
Definitions and statistical analysis
We calculated the following performance measures: positivity
rates for screening, detection rate, ICR, sensitivity, and specificity.
The results of cervical cancer screening were categorized as
negative (negative or benign disease of the cervix) or positive
(suspicious or highly suggestive of malignancy). Screening
assessment was based on Pap tests only.
The positivity rates (i.e., the proportion of screening assessments
that led to a recommendation for further work-up such as
colposcopy or biopsy to diagnose cancer) were calculated as the
number of positive findings per 100 screenings. The detection rate
was calculated as the number of cancer or CIS detected per 1,000
Cervical Cancer Screening in Korea
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diagnosed within 1 year of a negative screening per 1,000 negative
screenings. Sensitivity was defined as the probability of a positive
Pap test result given a finding of cancer within 1 year after
screening [true positive/(true positive+false negative)]. Specificity
was defined as the probability of a negative Pap test given no
finding of cancer within 1 year after a screening [true negative/
(true negative+false positive)].
Ninety-five percent confidence intervals (CI) were calculated for
detection rate, ICR, sensitivity, specificity, and percentage of CIS+
that were CIS. The age distribution was significantly different by
health insurance status (results not shown). Therefore, in multiple
logistic regression, odds ratios (OR) for detection rate, ICR, and
percentage of CIS among screen detected CIS+ were calculated
after adjusting for age group and health insurance status. SAS
software (version. 9.1; SAS Institute, Inc., Cary, NC, USA) was
used for all statistical calculations.
Results
Screening results
A total of 4,072,997 cervical cancer screenings were performed
from January 2005 to December 2006. About 74.3% of results
were classified as negative, and 19.1% were classified as benign.
The proportion of results classified as highly suggestive of
malignancy was 0.9%. Subjects in their forties and MAP recipients
had the highest percentage of results highly suggestive of
malignancy. The positivity rate was 6.6%. Women in their thirties
and NHI beneficiaries with a premium over 50% had the highest
percentage of abnormal results (Table 1).
Performance of Pap test in cervical cancer screening
A total of 3,539 CIS+ were detected by Pap test (1,297 ICC and
2,242 CIS). The detection rates for ICC, CIS, and CIS+ were
0.32, 0.55, and 0.87 per 1,000 screens, respectively. The detection
rate for ICC increased significantly with age (Ptrend,0.001),
whereas the detection rate for CIS decreased significantly with age
(Ptrend,0.001). In the logistic model, MAP recipients showed
significantly higher ORs of detection rate for CIS+ (OR: 1.35,
95% CI: 1.17–1.55) and ICC (OR: 1.67, 95% CI: 1.35–2.06) than
did NHI beneficiaries with a premium over 50% (Table 2).
In total, 503 interval cancers occurred within 1 year of a
negative screening result (ICR, 0.13/1000). The ICR increased
significantly with age (Ptrend,0.001). The OR of ICR was 1.66
times higher for MAP recipients than it was for the NHI
beneficiaries with premiums over 50% (Table 3).
The sensitivity of Pap test to detect CIS (79.8%, 95% CI: 78.3–
81.3) was higher than that for ICC (72.1%, 95% CI: 70.0–74.2%).
Overall the sensitivity and specificity of Pap test to detecting CIS
or ICC were 76.8% and 93.5%, respectively (Table 4).
Percentage of CIS among screen-detected CIS+
The percentages of CIS among screen-detected CIS+ varied
with age and health insurance (Table 5). Among CIS+ diagnosed
during the study period, 63.4% were CIS. The percentage of CIS
decreased significantly with age (Ptrend,0.001). The likelihood of
CIS was significantly lower for MAP recipients than for NHI
beneficiaries with premiums over 50%. Among screen-detected
CIS+, the percentage of CIS was 63.4% (95% CI: 61.8–65.0%),
and this percentage was higher among women aged 30–39 years
(80.5%, 95% CI: 75.3–85.7) than among those in all older age
groups [ranging from 60.0% (95% CI: 56.7–63.3%) to 50.0%
(95% CI: 47.1–52.9%) among women aged $50 years.
Ptrend,0.001].
Discussion
To our knowledge, this is the first study performed with detailed
screening results of Pap test from a nationwide cancer screening
program in Korea. The positivity rate for all Pap tests was 6.6%.
The number of ICC detected was 1,297 (0.32 per 1,000 screens),
and 503 interval cancer (0.13 per 1,000 negative screens) were
diagnosed. The sensitivity and specificity of Pap test for ICC were
72.1% and 93.4%, respectively. Approximately 63% of screen-
detected CIS+ turned out to be CIS.
In this study, the positivity rates decreased with age. In
accordance with previous studies, the percentage of abnormal
Pap tests results was highest at younger ages, which indicates that
Table 1. Percent distribution of Pap test results by age group and health insurance status in the Korean organized cancer
screening program, 2005–2006.
No. of Screenings, n Results, % Positivity
a, n (%)
Negative Benign Suspicious
Highly suggestive of
malignancy
Total 4,072,997 74.31 19.09 5.66 0.94 268,845 (6.60)
Age group, y
30–39 245,148 74.45 18.31 6.24 1.01 17,765 (7.25)
40–49 1,469,283 73.79 19.39 5.72 1.09 100,084 (6.81)
50–59 1,264,922 73.71 19.83 5.63 0.83 81,692 (6.46)
60+ 1,093,644 75.65 18.01 5.47 0.87 69,304 (6.34)
Health insurance status with average monthly premium level
MAP 206,672 75.15 18.74 4.85 1.26 12,626 (6.11)
NHI with premium under 50% 1,992,250 74.04 19.44 5.60 0.92 129,939 (6.52)
NHI with premium over 50% 1,874,064 74.50 18.76 5.80 0.93 126,278 (6.74)
MAP, Medical Aid Program; NHI, National Health Insurance.
aincluding suspicious and highly suggestive of malignancy.
doi:10.1371/journal.pone.0035469.t001
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and have higher rates of HPV infection [33].
ICC is usually preceded by a long phase of pre-invasive disease.
Therefore, the goal of screening is to identify and remove
significant precancerous lesions, in addition to prevention of
mortality. Several reports regarding the occurrence of in situ lesions
have been published based on data from population-based cancer
registries [34,35,36]. These data, however, do not specifically
report the incidence of screen-detected disease, as cancer registries
do not routinely collect information on screening practices.
Unscreened women are included in cancer registry statistics, but
estimates of CIS incidence based on data from population-based
cancer registries tend to underestimate the incidence of CIS
among screened women, as CIS is primarily detected by Pap test
during screening. Reports from individual screening programs and
case-series have provided estimates of the percentage of CIS.
However, there have been few reports of the occurrence of in situ
lesions among women who participate in large organized
screening programs [37,38]. In the present study, the CIS
detection rate was approximately 0.55 per 1,000 screenings, and
this rate decreased with age. Our results suggest that one case of
CIS is detected for approximately every 1,818 Pap tests
performed. This rate varies by age, ranging from approximately
1 in every 1,370 Pap tests among women aged 30–39 years to 1 in
every 2,439 Pap tests among women aged 50–59 years.
In general, cervical cancer incidence and mortality are the most
appropriate end points for validating the effectiveness of the Pap
test as a tool for screening. However, the use of these end points
requires a long observation period and a large number of subjects
to achieve adequate statistical power. For that reason, perfor-
Table 3. Interval cancer rates (ICR) of cervical cancer in screening participants aged 30 years and over, stratified by age group and
health insurance status, the Korean organized cancer screening program, 2005–2006.
No. of negative screening No. of interval cancer ICR
a (95% CI) aOR (95% CI)
b
Total 3,804,152 503 0.13 (0.12–0.14)
Age group, y
30–39 227,383 21 0.09 (0.05–0.13) 1.00
40–49 1,369,199 152 0.11 (0.09–0.13) 1.15 (0.73–1.82)
50–59 1,183,230 142 0.12 (0.10–0.14) 1.22 (0.77–1.94)
60+ 1,024,340 188 0.18 (0.15–0.21) 1.84 (1.17–2.90)
p-value for trend ,0.001
Health insurance status with average
monthly premium level
MAP 194,046 40 0.21 (0.15–0.27) 1.66 (1.18–2.34)
NHI (under 50%) 1,862,311 271 0.15 (0.13–0.17) 1.31 (1.09–1.58)
NHI (over 50%) 1,747,786 192 0.11 (0.09–0.13) 1.00
p-value for trend ,0.001
aOR, Adjusted odds ratio; CI, confidence interval; MAP, Medical Aid Program; NHI, National Health Insurance.
aper 1,000 negative screenings.
baOR is adjusted for variables in the table.
doi:10.1371/journal.pone.0035469.t003
Table 4. Sensitivity (sen) and specificity (spe) for detecting of cervical cancer by age group and health insurance status, the Korean
organized cancer screening program, 2005–2006.
CIS and ICC ICC CIS
Sen (95% CI) Spe (95% CI) Sen (95% CI) Spe (95% CI) Sen (95% CI) Spe (95% CI)
Total 76.8 (75.6–78.0) 93.5 (93.5–93.5) 72.1 (70.0–74.2) 93.4 (93.4–93.4) 79.8 (78.3–81.3) 93.4 (93.4–93.4)
Age group, y
30–39 76.2 (71.3–81.1) 92.8 (92.7–92.9) 67.2 (55.7–78.7) 92.8 (92.7–92.9) 78.8 (73.5–84.1) 92.8 (92.7–92.9)
40–49 75.4 (73.4–77.4) 93.3 (93.3–93.3) 70.0 (66.0–74.0) 93.2 (93.2–93.2) 77.5 (75.2–79.8) 93.2 (93.2–93.2)
50–59 75.7 (73.2–78.2) 93.6 (93.6–93.6) 70.9 (66.9–74.9) 93.6 (93.6–93.6) 79.2 (76.1–82.3) 93.6 (93.6–93.6)
60+ 79.5 (77.4–81.6) 93.8 (93.8–93.8) 74.7 (71.6–77.8) 93.7 (93.7–93.7) 85.1 (82.4–87.8) 93.7 (93.7–93.7)
Health insurance status with average monthly premium
level
MAP 78.4 (73.7–83.1) 94.0 (93.9–94.1) 73.2 (66.1–80.3) 93.9 (93.8–94.0) 83.7 (77.7–89.7) 93.9 (93.8–94.0)
NHI (under 50%) 76.9 (75.2–78.6) 93.6 (93.6–93.6) 72.0 (69.2–74.8) 93.5 (93.5–93.5) 80.3 (78.2–82.4) 93.5 (93.5–93.5)
NHI (over 50%) 76.3 (74.4–78.2) 93.3 (93.3–93.3) 71.9 (68.5–75.3) 93.3 (93.3–93.3) 78.7 (76.4–81.0) 93.3 (93.3–93.3)
CIS: carcinoma in situ; CI, confidence interval; ICC: invasive cervical cancer; MAP, Medical Aid Program; NHI, National Health Insurance.
doi:10.1371/journal.pone.0035469.t004
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cervical cancer screening [39], and key performance indicators
include cancer detection rates, percentage of small cancers
detected, and ICR [40]. These indicators are used as surrogate
markers of the effectiveness of an organized cancer screening
program; if the performance of an organized program is good,
then a reduction in mortality might be expected. In breast cancer
screening programs, ICR has been inversely associated with a
reduction in mortality, and surveillance for interval cancer is
widely used to monitor the performance of screening programs
[41,42]. Therefore, in the current study, we estimated the cancer
detection rate and ICR. The detection rates of ICC and CIS were
0.32 and 0.55 per 1,000 screens, respectively; the ICR was 0.13
per 1,000 negative screens. Few studies were found that evaluated
ICR based on data from population-based organized cervical
cancer screening program. Furthermore, most of these studies
assessed the negative screening history of women diagnosed with
ICC [43,44,45], making it difficult to directly compare the ICRs of
different studies due to differences in the study designs and
settings.
Whereas the CDR and ICR increased with age, the CIS
detection rate decreased with age (Ptrend,0.001). These trends
were associated with the incidence of ICC and CIS. According to
the KCCR, although the age-specific incidence of ICC increased
with age, the age-specific incidence of CIS was highest among
women in their forties, after which incidence decreased with age
[3]. With regard to health insurance status, the ORs for the
detection rate and ICR of ICC for MAP recipients were 1.67 and
1.66 times higher than those for NHI beneficiaries with premiums
over 50%. The high prevalence of ICC in women with low
socioeconomic status might affect the detection rate and ICR by
health insurance status. Several studies have reported an inverse
association between socioeconomic status (measured by indicators
such as education, income, or health insurance status) and ICC
[46,47,48].
Among CIS+ in the current study, MAP recipients were more
likely to have a positive screening result diagnosed as ICC than
CIS, compared with NHI beneficiaries with premiums over 50%.
There are some possible explanations for the relatively high
proportion of ICC in MAP recipients, for example they may have
been less likely to adhere to the recommended screening interval
considering the progression from pre-invasive lesions to ICC. In
this study, we could not identify the history of cervical cancer
screening among our study subjects. Previous studies have
reported that socioeconomic status is highly significantly negatively
associated with a longer screening interval [49,50]. In addition,
screening interval has been shown to be significantly positively
associated with a cytological prediction of diagnosis [10,49].
In this study, we found that the Pap test was more sensitive for
the detection of CIS (79.8%, 95% CI: 78.3–81.3) than ICC
(72.1%, 95% CI: 71.0–74.2). CIS after negative screening is much
less common than interval ICC as symptoms such as irregular
bleeding (e.g., bleeding between periods, with heavier or lighter
amounts than normal menstrual flow, or bleeding following
intercourse) might never become clinically apparent. Furthermore,
compared with ICC, less CIS cases were found during
opportunistic cervical cancer screening. This phenomenon may
lead to an overestimation of the ability of Pap tests to detect in situ
disease, and introduce bias in the sensitivity for detecting CIS.
The use of Pap test in cervical cancer screening has become
widespread. Based on 2009 nationally representative data from the
Korean National Cancer Screening Survey, 76.1% of Korean
women aged $30 years had at least one Pap test in her lifetime,
and 63.9% had one within the previous 2 years [51]. Our data
suggest that approximately 1 in every 1,667 Pap tests results in a
diagnosis of CIS. If early detection and treatment of CIS have
contributed to the recent decline in cervical cancer mortality in
Korea, independent of effects attributable to early detection and
treatment of invasive disease and of recent advances in cervical
cancer treatment, then some women who have been treated for
screen-detected CIS have benefited.
A number of limitations should be considered when reviewing
the results of the present study. They result primarily from the use
of data collected as part of the organized screening program. First,
screening program results were influenced by the policies used to
administer the program. For example, we could not distinguish
Table 5. Percentage of carcinoma in situ (CIS) cases among screen detected CIS+ by age and health insurance, the Korean
organized cancer screening program, 2005–2006.
No. of detected
a No. of CIS % of CIS (95% CI) aOR(95% CI)
b
Total 3,539 2,242 63.4 (61.8–65.0)
Age group, y
30–39 221 178 80.5 (75.3–85.7) 1.00
40–49 1,345 991 73.7 (71.3–76.1) 0.84 (0.49–1.46)
50–59 865 519 60.0 (56.7–63.3) 0.44 (0.25–0.77)
60+ 1,108 554 50.0 (47.1–52.9) 0.24 (0.13–0.42)
p-value for trend ,0.001
Health insurance status with average
monthly premium level
MAP 232 123 53.0 (46.6–59.4) 0.58 (0.33–1.01)
NHI (under 50%) 1,827 1,130 61.9 (59.7–64.1) 0.76 (0.59–0.99)
NHI (over 50%) 1,480 989 66.8 (64.4–69.2) 1.00
p-value for trend 0.011
aOR, adjusted odds ratio; CI, confidence interval; MAP, Medical Aid Program; NHI, National Health Insurance.
aIncluding CIS and invasive cervical cancer.
baORs adjusted for variables in the table.
doi:10.1371/journal.pone.0035469.t005
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viduals who reported symptoms were eligible for cervical cancer
screening through the organized cancer screening program for
ethical reasons, as they were more likely to have abnormal results
and require diagnostic follow-up compared with asymptomatic
participants. Second, we were unable to obtain records on Pap test
history, which might affect the performance of screening. Third,
although the organized cancer screening program is population-
based, our results might not be generalizable because of a low
participation rate. Overall, 19.8–22.4% of the invited women were
screened. Furthermore, our study was unable to control self-
selection bias because we did not have information about
participant characteristics such as education level, employment
status, and risk factors. In recent Korean study, participation in
organized screening was relatively more concentrated among the
lower-income groups [52]. Further study is needed to assess the
performance of organized cancer screening linked with opportu-
nistic screening. Fourth, the cervical cancer screening program
was conducted as part of a medical examination, and data
available to the NCSP and NHICSP do not include referral
information (i.e., colposcopy or biopsy) or diagnostic test results.
Finally, health insurance status and NHI premium level were used
as a proxy for socioeconomic status in the present study. However,
as we could not consider a participant’s educational level or
occupation as a proxy for socioeconomic status, it is possible that
the socioeconomic status of participants was not fully reflected.
Despite these limitations, we believe that our study also has
many strengths. To the best of our knowledge, this is the first study
to present detailed results of cervical cancer screening from the
nationwide screening program in Korea. In particular, we tried to
investigate the distribution of CIS in a population-based Pap test
program. The proportions of CIS were substantially different
according to socio-demographic factors. In particular, the
likelihood of a CIS diagnosis among CIS+ was significantly lower
among MAP recipients than among NHI beneficiaries with higher
income status. The difference in performance of cervical cancer
screening among different socio-demographic groups may indicate
an important influence of socio-demographic factors on preventive
behavior. The findings of the study support the critical need for
increasing efforts to raise awareness and provide more screening in
at-risk populations, specifically low-income groups.
Evaluation of screening performance enables us to assess the
interim effectiveness of cancer screening programs, to monitor the
performance of the various components of the screening process,
and to facilitate inter-jurisdictional comparisons. The evaluations
of performance indicators are the basis for the establishment of
standards for quality control. Further study is required to
determine the acceptable level of several indicators for cancer
screening policy and quality in Korea. Finally, establishment of
standards and continuous performance monitoring according to
socioeconomic status will help to reduce disparities in cervical
cancer detection and care.
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